Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
IQVIA HOLDINGS INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 216.91 USD | +1.31% | +2.31% | +5.87% | |
| Dec. 01 | Will Powell deliver an early Christmas present? |  |
| Dec. 01 | ANALYST RECOMMENDATIONS : Abbvie, Boeing, IBM, Lululemon Athletica, Meta Platforms... | |
ETFs positioned on Iqvia Holdings Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.74% | 1 M€ | -11.87% | ||
| 6.43% | 39 M€ | +14.89% | - | |
| 5.27% | 396 M€ | -3.81% | ||
| 3.87% | 6,059 M€ | -6.62% | ||
| 3.67% | 0 M€ | -.--% | - | |
| 3.45% | 0 M€ | -.--% | - | |
| 3.32% | 1,043 M€ | -6.92% | ||
| 3.32% | 5 M€ | -11.77% | ||
| 3.32% | 3 M€ | -15.62% | ||
| 3.25% | 2 M€ | +10.40% | - | |
| 2.92% | 1 M€ | -.--% | - | |
| 2.68% | 2 M€ | -.--% | ||
| 2.24% | 3 M€ | +6.04% | - | |
| 2.06% | 0 M€ | 0.00% | - | |
| 2.06% | 9 M€ | -3.53% | - | |
| 2.03% | 23 M€ | +20.60% | ||
| 1.91% | 1 M€ | +44.44% | - | |
| 1.91% | 0 M€ | +34.32% | - | |
| 1.85% | 69 M€ | -16.48% | ||
| 1.83% | 55 M€ | -11.84% | - | |
| 1.80% | 57 M€ | 0.00% | - | |
| 1.66% | 204 M€ | -8.40% | ||
| 1.64% | 799 M€ | -3.42% | ||
| 1.60% | 9 M€ | -7.34% | - | |
| 1.54% | 26 M€ | +9.77% | - | |
| 1.54% | 39 M€ | +11.40% | ||
| 1.47% | 3 M€ | -2.49% | - | |
| 1.39% | 909 M€ | -9.25% | - | |
| 1.34% | 9,272 M€ | +15.44% | ||
| 1.33% | 1 M€ | +2.21% | - | |
| 1.30% | 10,995 M€ | +18.55% | ||
| 1.27% | 30 M€ | +17.34% | - | |
| 1.27% | 21 M€ | +13.16% | - | |
| 1.20% | 2 M€ | -12.05% | ||
| 1.13% | 47 M€ | +26.96% | - | |
| 1.05% | 108 M€ | +18.25% | ||
| 1.05% | 33 M€ | +16.90% | ||
| 1.04% | 7 M€ | -11.20% | ||
| 0.90% | 37 M€ | -1.98% | - |
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Calendar
2024-02-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
216.91USD
Average target price
229.52USD
Spread / Average Target
+5.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.87% | 39 586 M $ | |
| +65.53% | 40 132 M $ | |
| -55.56% | 30 438 M $ | |
| -26.11% | 28 571 M $ | |
| +38.66% | 22 175 M $ | |
| -27.87% | 21 511 M $ | |
| +1.62% | 17 412 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ | |
| -22.09% | 10 212 M $ |
- Stock
- Equities
- Stock Iqvia Holdings Inc. - Nyse
- Funds and ETFs Iqvia Holdings Inc.
